MELBOURNE, Australia — August 14, 2025 — Leads & Copy — Propanc Biopharma, Inc. (OTC Pink: PPCB) announced the pricing of its underwritten public offering of 1,000,000 shares of common stock at $4.00 per share. The offering is expected to yield approximately $4 million in gross proceeds, which the Company intends to use for working capital and general business purposes.
The Company has granted the underwriter a 45-day option to purchase up to 150,000 additional shares of common stock. The offering is expected to close on August 18, 2025. On August 14, 2025, Propanc received approval to list its common stock on the Nasdaq Capital Market, with trading expected to commence on August 15, 2025.
The Company’s shares were previously quoted on the OTC Markets, Pink Tier, and ceased to be quoted at the close of business on August 14, 2025. The ticker symbol “PPCB” will remain unchanged.
D. Boral Capital LLC and Craft Capital Management LLC are acting as book running managers for the offering.
Electronic copies of the preliminary prospectus supplement and accompanying prospectus are available on the SEC’s website.
Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.
Contact: James Nathanielsz, +61-3-9882-0780, info@propanc.com
Investor Contact: irteam@propanc.com
Source: Propanc Biopharma, Inc.
